Lincoln Capital Corp bought a new position in shares of Mallinckrodt PLC (NYSE:MNK) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 20,000 shares of the company’s stock, valued at approximately $48,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Mallinckrodt by 0.3% during the 2nd quarter. BlackRock Inc. now owns 9,929,685 shares of the company’s stock valued at $91,155,000 after buying an additional 28,512 shares in the last quarter. Vanguard Group Inc. grew its holdings in Mallinckrodt by 18.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,809,305 shares of the company’s stock valued at $90,049,000 after buying an additional 1,527,591 shares in the last quarter. Morgan Stanley grew its holdings in Mallinckrodt by 1,395.5% during the 2nd quarter. Morgan Stanley now owns 3,275,676 shares of the company’s stock valued at $30,071,000 after buying an additional 3,056,636 shares in the last quarter. AQR Capital Management LLC grew its holdings in Mallinckrodt by 7.0% during the 2nd quarter. AQR Capital Management LLC now owns 2,517,723 shares of the company’s stock valued at $22,861,000 after buying an additional 164,434 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Mallinckrodt by 37.9% during the 2nd quarter. Invesco Ltd. now owns 2,038,239 shares of the company’s stock valued at $18,711,000 after buying an additional 559,939 shares in the last quarter.

Shares of Mallinckrodt stock traded up $0.02 on Friday, reaching $3.11. The company had a trading volume of 3,713,712 shares, compared to its average volume of 8,963,637. The firm has a market cap of $259.59 million, a price-to-earnings ratio of 0.39, a P/E/G ratio of 0.04 and a beta of 2.53. The company has a debt-to-equity ratio of 1.64, a current ratio of 1.07 and a quick ratio of 0.57. The firm’s 50-day moving average price is $2.69 and its two-hundred day moving average price is $7.12. Mallinckrodt PLC has a 1 year low of $1.43 and a 1 year high of $32.34.

Mallinckrodt (NYSE:MNK) last announced its earnings results on Tuesday, November 5th. The company reported $2.07 EPS for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.09. The firm had revenue of $743.70 million during the quarter, compared to analysts’ expectations of $770.56 million. Mallinckrodt had a positive return on equity of 24.36% and a negative net margin of 111.44%. The company’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.10 EPS. As a group, analysts anticipate that Mallinckrodt PLC will post 8.59 EPS for the current year.

Several equities analysts have weighed in on MNK shares. SunTrust Banks cut their price target on Mallinckrodt to $7.00 and set a “positive” rating for the company in a report on Monday, August 12th. BMO Capital Markets reiterated a “market perform” rating on shares of Mallinckrodt in a report on Thursday, September 5th. Jefferies Financial Group set a $2.00 target price on Mallinckrodt and gave the stock a “hold” rating in a report on Friday, September 6th. ValuEngine cut Mallinckrodt from a “hold” rating to a “sell” rating in a report on Tuesday, October 1st. Finally, Barclays set a $5.00 target price on Mallinckrodt and gave the stock a “hold” rating in a report on Tuesday, September 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $10.19.

About Mallinckrodt

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Further Reading: How is Preferred Stock Different from Common Stock?

Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).

Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.